Complement Therapeutics is an early stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases as well as developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform.

The company is a spin out from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade and its quantification. The CPM platform employs a unique methodology to quantify over 30 complement cascade proteins.

The lead investigational product (CTx001) is a gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.